

Special Issue

Immune Responses in Brain Cancer

Message from the Guest Editor

The interactions between tumor and immune response are of emerging interest in understanding both tumor biology and therapy failure. Thereby, there is a broad range of potential interactions between tumor cells and immune cells. In contrast to other organs, the brain represents a special situation: it is a site of immune privilege. However, this very traditional view has changed in recent years. Recent studies emphasize that there are complex immunological interactions between the brain and other organs. These novel developments may be of significant importance for advanced brain tumor therapy. Thereby, glioma represent the most frequent brain tumors of adults, with glioblastoma being the most malignant brain tumor, showing a devastating outcome. Despite intensive research, there are still no curative therapies available for glioma. In this Special Issue, we aim to highlight the importance of the immune response in brain tumors with recent studies on the interaction of the immune system and brain tumors to pave the way for novel immune-modulating therapies in brain tumors.

Guest Editor

Dr. Theo Kraus

Institute of Pathology, University Hospital Salzburg, Paracelsus Medical University, Müllner Hauptstr. 48, A-5020 Salzburg, Austria

Deadline for manuscript submissions

closed (15 September 2022)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/101800

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)